Eton Pharmaceuticals Inc
NASDAQ:ETON
Income Statement
Earnings Waterfall
Eton Pharmaceuticals Inc
Revenue
|
31.6m
USD
|
Cost of Revenue
|
-10.6m
USD
|
Gross Profit
|
21.1m
USD
|
Operating Expenses
|
-22.3m
USD
|
Operating Income
|
-1.2m
USD
|
Other Expenses
|
256k
USD
|
Net Income
|
-936k
USD
|
Income Statement
Eton Pharmaceuticals Inc
Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
1
N/A
|
1
N/A
|
1
+92%
|
1
-42%
|
1
+4%
|
0
-28%
|
0
-90%
|
12
+29 500%
|
15
+26%
|
16
+6%
|
22
+38%
|
12
-44%
|
16
+35%
|
19
+15%
|
21
+13%
|
24
+15%
|
29
+19%
|
33
+13%
|
32
-4%
|
|
Gross Profit | ||||||||||||||||||||||||
Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(2)
|
(2)
|
(3)
|
(3)
|
(2)
|
(5)
|
(5)
|
(7)
|
(8)
|
(8)
|
(9)
|
(11)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
0
N/A
|
(0)
N/A
|
(0)
-200%
|
(0)
-733%
|
10
N/A
|
13
+29%
|
13
+1%
|
19
+45%
|
10
-47%
|
12
+17%
|
14
+16%
|
14
+5%
|
16
+14%
|
21
+31%
|
24
+11%
|
21
-11%
|
|
Operating Income | ||||||||||||||||||||||||
Operating Expenses |
(11)
|
(10)
|
(10)
|
(15)
|
(16)
|
(19)
|
(19)
|
(20)
|
(22)
|
(23)
|
(27)
|
(23)
|
(24)
|
(23)
|
(21)
|
(25)
|
(26)
|
(25)
|
(23)
|
(25)
|
(25)
|
(25)
|
(22)
|
|
Selling, General & Administrative |
(5)
|
(5)
|
(5)
|
(5)
|
(6)
|
(6)
|
(8)
|
(9)
|
(10)
|
(12)
|
(13)
|
(14)
|
(15)
|
(14)
|
(14)
|
(15)
|
(17)
|
(18)
|
(19)
|
(19)
|
(19)
|
(19)
|
(19)
|
|
Research & Development |
(5)
|
(5)
|
(6)
|
(11)
|
(11)
|
(12)
|
(12)
|
(11)
|
(12)
|
(11)
|
(14)
|
(9)
|
(9)
|
(9)
|
(6)
|
(10)
|
(9)
|
(7)
|
(4)
|
(6)
|
(7)
|
(7)
|
(3)
|
|
Operating Income |
(11)
N/A
|
(10)
+4%
|
(10)
-1%
|
(15)
-44%
|
(16)
-4%
|
(18)
-17%
|
(19)
-2%
|
(20)
-7%
|
(21)
-6%
|
(22)
-6%
|
(27)
-21%
|
(13)
+53%
|
(11)
+17%
|
(10)
+4%
|
(2)
+85%
|
(15)
-873%
|
(14)
+4%
|
(11)
+21%
|
(9)
+21%
|
(9)
-3%
|
(4)
+58%
|
(1)
+62%
|
(1)
+18%
|
|
Pre-Tax Income | ||||||||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
1
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
(1)
|
(1)
|
(3)
|
(3)
|
(2)
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
3
|
0
|
3
|
4
|
4
|
0
|
|
Pre-Tax Income |
(11)
N/A
|
(11)
-1%
|
(13)
-14%
|
(17)
-34%
|
(17)
-1%
|
(19)
-12%
|
(18)
+5%
|
(20)
-9%
|
(21)
-7%
|
(23)
-7%
|
(28)
-22%
|
(14)
+51%
|
(11)
+20%
|
(11)
+4%
|
(2)
+82%
|
(12)
-533%
|
(12)
+4%
|
(9)
+25%
|
(9)
-1%
|
(6)
+29%
|
(0)
+96%
|
2
N/A
|
(1)
N/A
|
|
Net Income | ||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
|
Income from Continuing Operations |
(11)
|
(11)
|
(13)
|
(17)
|
(17)
|
(19)
|
(18)
|
(20)
|
(21)
|
(23)
|
(28)
|
(14)
|
(11)
|
(11)
|
(2)
|
(12)
|
(12)
|
(9)
|
(9)
|
(6)
|
(0)
|
2
|
(1)
|
|
Net Income (Common) |
(14)
N/A
|
(14)
-1%
|
(37)
-165%
|
(41)
-10%
|
(40)
+1%
|
(42)
-3%
|
(18)
+56%
|
(20)
-9%
|
(21)
-7%
|
(23)
-7%
|
(28)
-22%
|
(14)
+51%
|
(11)
+20%
|
(11)
+4%
|
(2)
+82%
|
(12)
-533%
|
(12)
+4%
|
(9)
+25%
|
(9)
-1%
|
(6)
+29%
|
(0)
+96%
|
2
N/A
|
(1)
N/A
|
|
EPS (Diluted) |
-0.85
N/A
|
-0.86
-1%
|
-2.11
-145%
|
-2.35
-11%
|
-2.27
+3%
|
-2.33
-3%
|
-1.03
+56%
|
-1.11
-8%
|
-1.02
+8%
|
-1.09
-7%
|
-1.33
-22%
|
-0.51
+62%
|
-0.43
+16%
|
-0.42
+2%
|
-0.08
+81%
|
-0.49
-513%
|
-0.47
+4%
|
-0.35
+26%
|
-0.36
-3%
|
-0.24
+33%
|
0
N/A
|
0.1
N/A
|
-0.04
N/A
|